HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Meyer, B. Articles by Berger, R. Search for Related Content PubMed PubMed Citation Articles by Meyer, B. Articles by Berger, R.

CLINICAL RESEARCH: HEART FAILURE AND CARDIAC TRANSPLANT

Flow-Mediated Vasodilation Predicts Outcome in Patients With Chronic Heart Failure

Comparison With B-Type Natriuretic Peptide

Department of Cardiology, Medical University of Vienna, Vienna, Austria.

Manuscript received November 24, 2004; revised manuscript received April 4, 2005, accepted April 13, 2005.

^_* Reprint requests and correspondence: Dr. Rudolf Berger, Department of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. (Email: rberger{at}gmx.at).

OBJECTIVES: The aim of this study was to assess the predictive potency of impaired endothelium-dependent flow-mediated vasodilation (FMD) in patients with chronic heart failure (CHF).

BACKGROUND: Chronic heart failure is associated with reduced FMD; the prognostic impact of this observation is unknown.

METHODS: Seventy-five ambulatory CHF patients (United Network of Organ Sharing [UNOS] status 2) with a left ventricular ejection fraction (LVEF) 30%, despite optimized medical therapy (angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, 100%; beta-blocker, 81%), were evaluated. Using high-resolution ultrasound, FMD of the brachial artery was assessed in addition to other neurohormonal, clinical, and hemodynamic variables. Age, gender, New York Heart Association (NYHA) functional class, LVEF, hemodynamic variables, B-type natriuretic peptide (BNP) levels, medical therapy, cardiovascular risk factors, and FMD were analyzed for prediction of the combined end point conversion to UNOS status 1 or death in a multivariate Cox model.

RESULTS: Up to three years, 21 patients (28%) converted to UNOS status 1, and 6 patients (8%) died. Univariate risk factors for the combined end point were log BNP (p = 0.0032), FMD (p = 0.0033), NYHA functional class (p = 0.0132), beta-blocker therapy (p = 0.0367), and mean blood pressure (p = 0.0406). In the multivariate analysis, only FMD (p = 0.0007), log BNP (p = 0.0032), and mean blood pressure (p = 0.0475) were independently related to the combined end point. In the Kaplan-Meier plot, significantly more patients with FMD <6.8% (median) reached the combined end point, as compared with patients with FMD >6.8% (p = 0.004).

CONCLUSIONS: In CHF, impaired FMD is a strong, independent predictor of conversion to UNOS status 1 or death.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   BNP = B-type natriuretic peptide   CHF = chronic heart failure   DCM = dilated cardiomyopathy   FMD = (endothelium-dependent) flow-mediated vasodilation   HTx = heart transplantation   ICM = ischemic cardiomyopathy   LVEF = left ventricular ejection fraction   NMD = nitroglycerin-mediated vasodilation   NYHA = New York Heart Association   ROC = receiver-operating characteristic   UNOS = United Network for Organ Sharing

This article has been cited by other articles:

				J. Yeboah, J. R. Crouse, F.-C. Hsu, G. L. Burke, and D. M. Herrington Brachial Flow-Mediated Dilation Predicts Incident Cardiovascular Events in Older Adults: The Cardiovascular Health Study Circulation, May 8, 2007; 115(18): 2390 - 2397. [Abstract] [Full Text] [PDF]

				I. J. Kullo and A. R. Malik Arterial Ultrasonography and Tonometry as Adjuncts to Cardiovascular Risk Stratification J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1413 - 1426. [Abstract] [Full Text] [PDF]

				D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF]

				E. Roig Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E12 - E17. [Abstract] [Full Text] [PDF]

				J. Butler More Risk Factors Affecting Heart Failure Outcomes!: Time for Hope or Despair? J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1027 - 1028. [Full Text] [PDF]